Prakt. lékáren. 2016; 12(1): 26-28 | DOI: 10.36290/lek.2016.006

New options for treating eosinophilic esophagitis by using compounded medication

Alena Menclová1, Michal Hojný1, Martina Dulavová1, Martina Drábková1, Jan Martínek2, David Vetchý3, Jan Muselík3
1 Ústavní lékárna IKEM, Praha
2 Klinika hepatogastroenterologie IKEM, Praha
3 Ústav technologie léků, Farmaceutická fakulta, Veterinární a farmaceutická univerzita Brno

This article deals with budesonide, a new pharmaceutical substance for extemporaneus preparation. Thanks to magistraliter

preparation we have new possibility of treatment eosinophilic esophagitis by an extemporaneously prepared highly viscous

budesonide suspension. The results of the paper evaluate stability and safety profile of this suspension.

Keywords: budesonide, corticosteroids, extemporaneus preparation, Eosinophilic Esophagitis

Published: February 1, 2016  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Menclová A, Hojný M, Dulavová M, Drábková M, Martínek J, Vetchý D, Muselík J. New options for treating eosinophilic esophagitis by using compounded medication. Pharmacy for Practice. 2016;12(1):26-28. doi: 10.36290/lek.2016.006.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Český lékopis 2009. 1. vyd. ed. Praha: Grada Publishing; 2009.
    2. Trissel LA. Stability of compounded formulations. Washington DC: American Pharmacists Association; 2009. p. 77-80.
    3. Borovansky A. Farmaceutická chemie (Farmakochemie) VII. Léčiva s účinkem na endokrinní systém (hormony). Brno: Veterinární a farmaceutická univerzita Brno; 2007. p. 157.
    4. Drugbank: Budesonide. Dostupné z: http://www.drugbank.ca/drugs/DB01222 [cit. 2015-08-22].
    5. Molina-Infante J, Lucendo AJ. Update on topical steroid therapy for eosinophilic esophagitis. Gastroenterol Hepatol. 2015; 38(6): 388-397. Go to original source... Go to PubMed...
    6. Liacouras CA, Furuta GT, Hirano I, Atkins D, Attwood SE, Bonis PA, et al. Eosinophilic esophagitis: updated consensus recommendations for children and adults. J Allergy Clin Immunol. 2011; 128(1): 3-20 e6; quiz 1-2. Go to original source... Go to PubMed...
    7. Lucendo AJ, De Rezende L, Comas C, Caballero T, Bellon T. Treatment with topical steroids downregulates IL-5, eotaxin-1/CCL11, and eotaxin-3/CCL26 gene expression in eosinophilic esophagitis. Am J Gastroenterol. 2008; 103(9): 2184-2193. Go to original source... Go to PubMed...
    8. Blanchard C, Mingler MK, Vicario M, Abonia JP, Wu YY, Lu TX, et al. IL-13 involvement in eosinophilic esophagitis: transcriptome analysis and reversibility with glucocorticoids. J Allergy Clin Immunol. 2007; 120(6): 1292-1300. Go to original source... Go to PubMed...
    9. Dellon ES, Liacouras CA. Advances in clinical management of eosinophilic esophagitis. Gastroenterology. 2014; 147(6): 1238-1254. Go to original source... Go to PubMed...
    10. Aceves SS, Bastian JF, Newbury RO, Dohil R. Oral viscous budesonide: a potential new therapy for eosinophilic esophagitis in children. Am J Gastroenterol. 2007; 102(10): 2271-2279; quiz 80. Go to original source... Go to PubMed...
    11. Dohil R, Newbury R, Fox L, Bastian J, Aceves S. Oral viscous budesonide is effective in children with eosinophilic esophagitis in a randomized, placebo-controlled trial. Gastroenterology 2010; 139(2): 418-429. Go to original source... Go to PubMed...
    12. Rubinstein E, Lee JJ, Fried A, Logvinenko T, Ngo P, McDonald D, et al. Comparison of 2 delivery vehicles for viscous budesonide to treat eosinophilic esophagitis in children. J Pediatr Gastroenterol Nutr. 2014; 59(3): 317-320. Go to original source... Go to PubMed...
    13. Gupta SK, Vitanza JM, Collins MH. Efficacy and safety of oral budesonide suspension in pediatric patients with eosinophilic esophagitis. Clin Gastroenterol Hepatol. 2015; 13(1): 66-76 e3. Go to original source... Go to PubMed...
    14. Straumann A, Conus S, Degen L, Felder S, Kummer M, Engel H, et al. Budesonide is effective in adolescent and adult patients with active eosinophilic esophagitis. Gastroenterology 2010; 139(5): 1526-1537, 37 e1. Go to original source... Go to PubMed...
    15. Francis DL, Foxx-Orenstein A, Arora AS, Smyrk TC, Jensen K, Nord SL, et al. Results of ambulatory pH monitoring do not reliably predict response to therapy in patients with eosinophilic oesophagitis. Aliment Pharmacol Ther. 2012; 35(2): 300-307. Go to original source... Go to PubMed...
    16. Dellon ES, Sheikh A, Speck O, Woodward K, Whitlow AB, Hores JM, et al. Viscous topical is more effective than nebulized steroid therapy for patients with eosinophilic esophagitis. Gastroenterology 2012; 143(2): 321-324 e1. Go to original source... Go to PubMed...

    Return to the content


    Pharmacy for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.